Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA, IMpower150 Study Group

Open source

DOI: 10.1016/s2213-2600(19)30084-0
Published: 2019 May
Container: The Lancet. Respiratory medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2213-2600-19-30084-0,
  title = {Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.},
  author = {Reck M and Mok TSK and Nishio M and Jotte RM and Cappuzzo F and Orlandi F and Stroyakovskiy D and Nogami N and Rodríguez-Abreu D and Moro-Sibilot D and Thomas CA and Barlesi F and Finley G and Lee A and Coleman S and Deng Y and Kowanetz M and Shankar G and Lin W and Socinski MA and IMpower150 Study Group},
  year = {2019},
  journal = {The Lancet. Respiratory medicine},
  doi = {10.1016/s2213-2600(19)30084-0},
  url = {https://doi.org/10.1016/s2213-2600(19)30084-0}
}

RIS

TY  - JOUR
TI  - Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
AU  - Reck M
AU  - Mok TSK
AU  - Nishio M
AU  - Jotte RM
AU  - Cappuzzo F
AU  - Orlandi F
AU  - Stroyakovskiy D
AU  - Nogami N
AU  - Rodríguez-Abreu D
AU  - Moro-Sibilot D
AU  - Thomas CA
AU  - Barlesi F
AU  - Finley G
AU  - Lee A
AU  - Coleman S
AU  - Deng Y
AU  - Kowanetz M
AU  - Shankar G
AU  - Lin W
AU  - Socinski MA
AU  - IMpower150 Study Group
PY  - 2019
JO  - The Lancet. Respiratory medicine
DO  - 10.1016/s2213-2600(19)30084-0
UR  - https://doi.org/10.1016/s2213-2600(19)30084-0
ER  -

APA

M, R., TSK, M., M, N., RM, J., F, C., F, O., D, S., N, N., D, R., D, M., CA, T., F, B., G, F., A, L., S, C., Y, D., M, K., G, S., W, L., MA, S., & Group, I. S. (2019). Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.. The Lancet. Respiratory medicine. https://doi.org/10.1016/s2213-2600(19)30084-0

Source records

pubmed · retrieved 2026-09-26T07:21:18.187Z